KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Short-term Investments (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Short-term Investments for 6 consecutive years, with $278.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short-term Investments fell 10.59% year-over-year to $278.6 million, compared with a TTM value of $278.6 million through Sep 2025, down 10.59%, and an annual FY2024 reading of $275.0 million, down 8.81% over the prior year.
  • Short-term Investments was $278.6 million for Q3 2025 at Aurinia Pharmaceuticals, up from $262.1 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $311.6 million in Q3 2024 and bottomed at $191.7 million in Q1 2021.
  • Average Short-term Investments over 5 years is $264.5 million, with a median of $272.5 million recorded in 2023.
  • The sharpest move saw Short-term Investments surged 49.3% in 2022, then dropped 11.76% in 2025.
  • Year by year, Short-term Investments stood at $234.2 million in 2021, then grew by 26.07% to $295.2 million in 2022, then increased by 2.17% to $301.6 million in 2023, then dropped by 8.81% to $275.0 million in 2024, then increased by 1.3% to $278.6 million in 2025.
  • Business Quant data shows Short-term Investments for AUPH at $278.6 million in Q3 2025, $262.1 million in Q2 2025, and $246.5 million in Q1 2025.